Simultaneous determination of acyclovir, ganciclovir, and (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine in human plasma using high-performance liquid chromatography

Biomedical Chromatography

Volumn 23, Issue 8, 2009, Pages 822-827

  Weller, Dennis R ^a   Balfour, Henry H ^a   Vezina, Heather E ^a,b,c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c NONE   (United States)

Author keywords

Acyclovir; Chromatography; Epstein Barr virus; Ganciclovir; H2G

Indexed keywords

METHANOL; PLASMA (HUMAN); POSITIVE IONS; VIRUSES;

ACYCLOVIR; EPSTEIN-BARR VIRUS; GANCICLOVIR; GUANINE; H2G; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN PLASMAS; IN-VITRO; IN-VIVO; SIMULTANEOUS DETERMINATIONS;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

9 [4 HYDROXY 2 (HYDROXYMETHYL)BUTYL]GUANINE; ACICLOVIR; GANCICLOVIR; PENCICLOVIR; PERCHLORIC ACID; VALACICLOVIR;

ACID PRECIPITATION; ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG SELECTIVITY; DRUG STABILITY; EPSTEIN BARR VIRUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; QUANTITATIVE ANALYSIS; ULTRAVIOLET RADIATION; VIRUS INFECTION;

HUMAN HERPESVIRUS 4;

EID: 70349506016     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1192     Document Type: Article

References (24)

1. Bacon TH and Boyd MR. Activity of penciclovir against Epstein-Barr virus. Antimicrobial Agents and Chemotherapy 1995; 39: 1599-1602.
2. Balfour HH Jr., Hokanson KM, Schacherer RM, Fietzer CM, Schmeling DO, Holman CJ, Vezina HE and Brundage RC. A virologic pilot study of valacyclovir in infectious mononucleosis. Journal of Clinical Virology 2007; 39: 16-21.
3. Colby BM, Shaw JE, Elion GB and Pagano JS. Effect of acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein-Barr virus DNA replication. Journal of Virology 1980; 34: 560-568.
4. Dao YJ, Jiao Z and Zhong MK. Simultaneous determination of acyclovir, ganciclovir, and penciclovir in human plasma by high-performance liquid chromatography with fluorescence detection. Journal of Chromatography B 2008; 867: 270-276.
5. DeLorenze GN, Munger KL, Lennette ET, Orentreich N, Vogelman JH and Ascherio A. Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Archives of Neurology 2006; 63: 839-844.
6. Funch DP, Walker AM, Schneider G, Ziyadeh NJ and Pescovitz MD. Ganciclovir and acyclovir reduce the risk of post-transplant lympho-proliferative disorder in renal transplant recipients. American Journal of Transplantation 2005; 5: 2894-2900.
7. Glaser SL, Lin RJ, Stewart SL, Ambinder RF, Jarrett RF, Brousset P, Pallesen G, Gulley ML, Khan G, O'Grady J, Hummel M, Preciado MV, Knecht H, Chan JK and Claviez A. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. International Journal of Cancer 1997; 70: 375-382.
8. Humar A, Hebert D, Davies HD, Humar A, Stephens D, O'Doherty B and Allen U. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related postransplant lymphoproliferative disorder. Transplantation 2006; 81: 856-861.
9. Katz BZ, Pahl E, Crawford SE, Kostyk MC, Rodgers S, Seshadri R, Proytcheva M and Pophal S. Case-control study of risk factors for the development of post-transplant lymphoproliferative disease in a pediatyric heart transplant cohort. Pediatric Transplantation 2007; 11: 58-65.
10. Kishino S, Takekuma Y, Sugawara M, Shimamura T, Furukawa H, Todo S and Miyazaki K. Liquid chromatographic method for the determination of ganciclovir and/or acyclovir in human plasma using pulsed amperometric detection. Journal of Chromatography B 2002; 780: 289-294.
11. Lin JC, Smith MC and Pagano JS. Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus. Journal of Virology 1984; 50: 50-55.
12. Lowe DM, Alderton WK, Ellis MR, Parmar V, Miller WH, Roberts GB, Fyfe JA, Gaillard R, Ertl P, Snowden W and Littler E. Mode of action of (R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine against herpesviruses. Antimicrobial Agents and Chemotherapy 1995; 39: 1802-1808.
13. Markin RS, Linder J. Zuerlein K, Mroczek E, Grierson HL, Brichacek B and Purtilo DT. Hepatitis in fatal infectious mononucleosis. Gastroenterology 1987; 93: 1210-1217.
14. McMullin CM, Kirk B, Sunderland J, White LO, Reeves DS and MacGowan AP. A simple high performance liquid chromatography (HPLC) assay for aciclovir and ganciclovir in serum. Journal of Antimicrobial Chemotherapy 1996; 38: 739-740.
15. Mroczek EC, Weisenburger DD, Grierosn HL, Markin R and Purtilo DT. Fatal infectious mononucleosis and virus-associated hemophagocytic syndrome. Archives of Pathology and Laboratory Medicine 1987; 111: 530-535.
16. Newell KA, Alonso EM, Whitington PF, Bruce DS, Millis JM, Piper JB, Woodle ES, Kelly SM, Koeppen H, Hart J, Rubin CM and Thistlethwaite JR Jr. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation 1996; 62: 370-375.
17. Pathmanathan R, Prasad U, Chandrika G, Sadler R, Flynn K and Raab-Traub N. Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. American Journal of Pathology 1995; 146: 1355-1367.
18. Perrottet N, Beguin A, Meylan P, Pascual M, Manuel O, Buclin T, Biollaz J and Decosterd LA. Determination of aciclovir and ganciclovir in human plasma by liquid chromatography-spectrofluorimetric detection and stability studies in blood samples. Journal of Chromatography B 2007; 852: 420-429.
19. Sauce D, Larsen M, Curnow SJ, Leese AM, Moss PAH, Hislop AD, Salmon M and Rickinson AB. EBV-associated mononucleosis leads to a long-term global deficit in T-cell responsiveness to IL-15. Blood 2006; 108: 11-18.
20. Smith JM, Corey L, Healey PJ, Davis CL and McDonald RA. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients. Transplantation 2007; 83: 1423-1428.
21. Tattevin P, Le Tulzo Y, Minjolle S, Person A, Chapplain JM, Arvieux C, Thomas R and Michelet C. Increasing incidence of severe Epstein-Barr virus-related infectious mononucleosis: surveillance study. Journal of Clinical Microbiology 2006; 44: 1873-1874.
22. Teshima D, Otsubo K, Yoshida T, Itoh Y and Oishi R. A simple and simultaneous determination of acyclovir and ganciclovir in human plasma by high-performance liquid chromatography. Biomedical Chromatography 2003; 17: 500-503.
23. Torre D and Tambini R. Acyclovir for treatment of infectious mononucleosis: a meta-analysis. Scandinavian Journal of Infectious Diseases 1999; 31: 543-547.
24. United States Department of Health and Human Services Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation, May 2001; http://www.fda.gov/cder/guidance/4252fnl.htm (accessed 6 October 2008).